TDMS No. 95003 - 06	P18: INCII	DENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WIT AVERAGE SEVERITY GRADES[b]	Date Report Requested: 10/09/2009
Test Type: CHRONIC		Methyl trans-styryl ketone	Time Report Requested: 14:36:21
Route: SKIN APPLICATION		CAS Number: 1896-62-4	First Dose M/F: 04/26/04 / 04/26/04
Species/Strain: MICE/B6C3F1			Lab: SRI
		F1_M3	
C Number:	C95003C		
Lock Date:	01/29/2007		

Cage Range:

Date Range:

Reasons For Removal:

Removal Date Range:

Treatment Groups:

Study Gender:

TDMSE Version:

ALL

ALL

ALL

ALL

Both

2.1.0

Include ALL

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Disposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths					
Accidently Killed	4	1	0	_	
Moribund Sacrifice Natural Death	4 12	2 12	8 7	5 7	
Survivors	12	12	1	7	
Terminal Sacrifice	34	35	35	38	
Animals Examined Microscopically	50	50	50	50	
LIMENTARY SYSTEM					
Gallbladder	(40)	(38)	(44)	(38)	
Inflammation, Acute				1 [1.0]	
Intestine Large, Cecum	(41)	(46)	(46)	(46)	
Intestine Large, Colon	(39)	(43)	(44)	(43)	
Edema Intestine Large, Rectum	(41)	(43)	1 [2.0] (46)	(46)	
Inflammation, Acute	(+1)	(43) 1 [1.0]	(40)	(40)	
Intestine Small, Duodenum	(40)	(42)	(44)	(43)	
Hemorrhage	(/	()	()	1 [2.0]	
Intestine Small, Ileum	(40)	(44)	(45)	(43)	
Inflammation, Acute			1 [2.0]		
Inflammation, Chronic	(44)	(40)		1 [3.0]	
Intestine Small, Jejunum	(41)	(42)	(45)	(44)	
Inflammation, Acute Inflammation, Chronic	1 [2.0]		1 [1.0]	1 [4.0]	
Mineralization		1 [1.0]		- [0]	
Necrosis	1 [1.0]	1 [1.0]	1 [1.0]		
Liver	(50)	(50)	(50)	(49)	
Angiectasis	2 [3.0]		1 [3.0]		
Basophilic Focus	5	5	3	3	
Basophilic Focus, Multiple			4 [0 0]	1	
Bile Stasis Clear Cell Focus	17	2 [2.5] 18	1 [3.0] 15	18	
	1 [2.0]	2 [3.0]	10	10	
Congestion					

a - Number of animals examined microscopically at site and number of animals with lesion

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

TDMS No. 95003 - 06 P18: INCID

Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Eosinophilic Focus17Fatty Change1 [4.0]Hematopoietic Cell Proliferation4 [1.8]Hematopoietic Cell Proliferation2 [2 5]	14 1 [1.0] 2 [2.5]	16 4 [1.3]	13 7 [1.0]	
Hematopoietic Cell Proliferation 4 [1.8]		4 [1.3]	7 [1.0]	
		4 [1.3]	7 [1.0]	
	2 [2.5]			
Hemorrhage 2 [2.5]				
Hyperplasia, Lymphoid 1 [2.0]				
Inflammation, Acute 1 [3.0]				
Inflammation, Chronic	2 [2.5]			
Mixed Cell Focus 2	5	2	4	
Necrosis, Focal 15 [1.8]	7 [2.6]	8 [2.6]	6 [3.0]	
Thrombosis		1 [2.0]	1 [1.0]	
Centrilobular, Necrosis 1 [2.0]				
Hepatocyte, Hypertrophy	1 [2.0]		1 [2.0]	
Hepatocyte, Vacuolization Cytoplasmic 1 [2.0]	2 [2.0]	1 [2.0]	.[]	
Mesentery (6)	(12)	(8)	(6)	
Fibrosis	1 [2.0]	1 [2.0]	1 [2.0]	
Hemorrhage	3 [2.7]	. [=:•]	1 [2.0]	
Inflammation, Chronic	0[=]		1 [3.0]	
Artery, Hyperplasia			1 [3.0]	
Fat, Necrosis 5 [2.2]	5 [2.0]	7 [2.0]	4 [1.8]	
Pancreas (49)	(50)	(50)	(49)	
Angiectasis 1 [2.0]	(00)	(88)	(10)	
Inflammation, Chronic	1 [2.0]			
Lipomatosis	1 [2.0]	1 [3.0]		
Metaplasia, Hepatocyte 1 [1.0]	1 [2:0]	1 [0:0]		
Salivary Glands (50)	(50)	(50)	(50)	
Atrophy 1 [2.0]	(55)	2 [1.5]	(50)	
Hyperplasia, Lymphoid 12 [2.0]	13 [2.0]	11 [2.0]	10 [2.0]	
Inflammation, Chronic Active	1 [2.0]	11 [2:0]	10 [2:0]	
Mineralization 1 [1.0]	2 [1.0]	1 [1.0]		
Necrosis	1 [3.0]	1[1:0]		
Stomach, Forestomach (50)	(50)	(50)	(50)	
Cyst	(50)	(30)	1 [2.0]	
Edema	1 [2.0]	1 [2.0]	1 [2.0]	
Erosion 4 [2.0]	1 [2.0]	2 [2.0]		
Inflammation, Chronic	3 [2.0]	3 [1.7]	3 [2.0]	
Ulcer 2 [2.5]	2 [3.0]	5 [2.4]	3 [2.0] 1 [2.0]	
Epithelium, Hyperplasia 5 [2.4]	2 [3.0] 7 [2.4]	7 [2.1]	6 [2.3]	
Stomach, Glandular (47)	(49)	(49)	(48)	
Cyst 2 [2.0]	(49) 1 [2.0]	(49) 13 [2.0]		
Erosion 2 [2.0]	1 [2.0] 1 [1.0]	3 [1.7]	5 [2.0] 1 [1.0]	
	1 [1.0]	5[1.7]	1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

TDMS No. 95003 - 06

Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Hemorrhage Inflammation, Acute Inflammation, Chronic Metaplasia, Squamous Mineralization	1 [1.0] 1 [2.0]	2 [1.5] 3 [1.0]	5 [1.8] 1 [2.0] 2 [1.0]	1 [1.0] 1 [2.0] 2 [2.0] 1 [1.0]	
Necrosis Ulcer Epithelium, Hyperplasia Tooth Malformation	1 [4.0] 2 [3.5] (1) 1 [2.0]	2 [2.5] 1 [4.0] (1) 1 [2.0]	1 [1.0] (0)	(0)	
CARDIOVASCULAR SYSTEM Heart Cardiomyopathy Mineralization Thrombosis Artery, Inflammation, Chronic	(50) 11 [1.0]	(50) 7 [1.1] 1 [3.0]	(50) 8 [1.3] 2 [1.0]	(50) 4 [1.5] 1 [1.0] 1 [2.0]	
ENDOCRINE SYSTEM					
Adrenal Cortex Accessory Adrenal Cortical Nodule Degeneration, Fatty Hyperplasia	(50) 2 [2.0] 4 [1.0] 2 [4.0]	(50) 1 [1.0] 12 [1.7]	(50) 2 [1.5] 9 [1.4]	(49) 8 [1.4] 6 [1.3]	
Hyperplasia, Focal Hypertrophy, Focal Capsule, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic Angiectasis Hyperplasia Parathyroid Gland Cyst	1 [1.0] 16 [2.1] 38 [2.1] (49) 4 [1.0] (50) 1 [3.0] 28 [1.8] (48) 2 [2.0]	1 [2.0] 16 [2.1] 40 [2.0] (50) 2 [1.5] (50) 23 [1.9] (47) 1 [2.0]	1 [2.0] 20 [2.1] 40 [1.7] (50) 1 [1.0] (50) 28 [1.8] (48) 1 [2.0]	12 [2.3] 36 [1.8] (49) 5 [1.2] (49) 19 [1.5] (45)	
Pituitary Gland Pars Distalis, Cyst Pars Distalis, Hyperplasia, Focal Pars Intermedia, Cyst	(49) 4 [2.0]	(49) 4 [2.0] 1 [2.0]	(50) 5 [2.0] 1 [1.0] 1 [2.0]	(49) 3 [2.0] 2 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Seminal Vesicle

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Thyroid Gland	(50)	(49)	(50)	(49)	
Cyst Follicle, Degeneration, Focal Follicular Cell, Hyperplasia, Focal	1 [2.0]	1 [3.0]	1 [2.0]	2 [3.5] 1 [1.0]	
GENERAL BODY SYSTEM					
Tissue NOS Fibrosis	(2) 1 [2.0]	(2)	(2)	(0)	
GENITAL SYSTEM					
Epididymis	(50)	(50)	(50)	(50)	
Amyloid Deposition, Chronic Angiectasis			1 [2.0]	1 [2.0]	
Fibrosis		1 [3.0]		1 [2.0]	
Granuloma Sperm		.[]	2 [3.0]		
Hemorrhage		1 [3.0]			
Inflammation, Chronic	1 [2.0]	3 [2.0]		3 [1.3]	
Necrosis	1 [3.0]				
Spermatocele		1 [3.0]		1 [2.0]	
Penis	(0)	(0)	(2)	(0)	
Congestion			1 [2.0]		
Inflammation, Acute	(50)	(50)	1 [1.0]	(50)	
Preputial Gland Atrophy	(50)	(50)	(50)	(50)	
Cyst	1 [3.0] 3 [2.0]	3 [2.0]	7 [2.0]	5 [2.0]	
Hyperplasia	0 [2.0]	5 [2.0]	1 [2.0]	٥ [٢.0]	
Hyperplasia, Squamous	1 [2.0]		· [2.0]		
Inflammation, Chronic	13 [2.2]	18 [2.2]	12 [2.1]	15 [2.3]	
Inflammation, Chronic Active	1 [4.0]	3 [2.3]	4 [2.5]	6 [3.0]	
Prostate	(50)	(50)	(50)	(48)	
Angiectasis		1 [2.0]		1 [2.0]	
Cyst				2 [2.5]	
Inflammation, Chronic	1 [2.0]	8 [2.3]	6 [2.0]	6 [1.7]	
Necrosis	1 [1.0]				
Polyarteritis				2 [2.0]	
Epithelium, Hyperplasia	27 [1.5]	20 [1.5]	16 [1.6]	25 [1.5]	
Cominal Vasiala	(EO)			(40)	

a - Number of animals examined microscopically at site and number of animals with lesion

(50)

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

(50)

(49)

(50)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
1 [2 0]	1 [3.0]		1 [2.0]	
			2 [3.0]	
	4 [2.0]		1 [1.0]	
			1 [1.0]	
(50)	(50)		(50)	
0 [4 7]	0 10 01		1 [3.0]	
6[1.7]	3 [2.3]	1 [2.0] 1 [2.0]	1 [3.0]	
(50)	(50)	(50)	(50)	
		4 10 01	1 [2.0]	
		1 [2.0]	1 [2 0]	
(5)	(5)	(4)	(6)	
	(0)	(+)	(0)	
		1 [2.0]	1 [4.0]	
2 [3.0]		1 [2.0]		
1 [2.0]	4 [0 0]		1 [3.0]	
4 [2 0]	1 [3.0]			
	(46)	(50)	(40)	
	(40)	(50)		
0[1.7]				
1 [2.0]	1 [2.0]		. [=.0]	
	1 [2.0]		6 [3.0]	
	1 [4.0]		1 [4.0]	
	4 [1.3]	4 [2.0]		
		0 [0 0]	1 [4.0]	
3 [3.0] 2 [2 7]	2 [2 2]		2 [2 5]	
	ა [೭.ა]	۲ [۲.0]	2 [3.3] 1 [4 0]	
4 [3.0]	2 [3.5]	2 [2.5]		
-	(5) 1 [3.0] 1 [3.0]	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Hyperplasia, Plasma Cell	2 [2.5]	2 [3.5]	2 [3.0]	4 [4.0]
Infiltration Cellular, Neutrophil	2 [2.5]	1 [2.0]	2 [2.0]	3 [2.3]
Inflammation, Chronic	1 [1.0]			1 [4.0]
Spleen	(48)	(47)	(49)	(49)
Fibrosis			1 [2.0]	
Hematopoietic Cell Proliferation Necrosis	11 [3.2]	16 [3.4]	16 [3.6]	20 [3.3] 1 [2.0]
Pigmentation		1 [2.0]		
Lymphoid Follicle, Atrophy	1 [2.0]	4 [2.5]	2 [2.5]	2 [1.5]
Lymphoid Follicle, Hyperplasia		1 [1.0]	2 [2.0]	3 [1.3]
Thymus	(44)	(48)	(46)	(40)
Cyst	10 [2.0]	7 [2.0]	4 [2.0]	4 [2.0]
ITEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Infiltration Cellular				1 [4.0]
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		1	1	
Edema		2 [2.0]	1 [2.0]	5 (4 0)
Hyperkeratosis	1 [2.0]	3 [2.7]	1 [1.0]	5 [1.0]
Hyperplasia, Melanocyte Inflammation, Chronic		1 [3.0]	0 [4 0]	0 [4 0]
Metaplasia, Osseous		3 [2.0]	2 [1.0]	6 [1.0]
Ulcer		1 [4.0] 1 [4.0]	1 [4.0]	
Epidermis, Hyperplasia		2 [3.5]	i [4.0]	4 [1.0]
Epidermis, Site Of Application,	7 [1.1]	13 [1.5]	29 [1.2]	37 [1.6]
Hyperplasia	, []	10[1.0]	20[1.2]	57 [1.0]
Prepuce, Hyperkeratosis			1 [3.0]	
Site Of Application, Erosion		1 [2.0]	. [0.0]	
Site Of Application, Fibrosis		1 [1.0]	5 [2.0]	1 [1.0]
Site Of Application, Hyperkeratosis	17 [1.2]	19 [1.7]	26 [1.3]	40 [1.6]
Site Of Application, Hyperplasia,		1 [1.0]	23 [1.2]	44 [2.2]
Melanocyte				
Site Of Application, Inflammation,	1 [1.0]	8 [1.4]	15 [1.2]	43 [1.7]
Chronic				
Site Of Application, Ulcer		2 [3.0]	2 [3.5]	5 [1.6]
Site Of Application, Subcutaneous				1 [2.0]
Tissue, Hemorrhage				

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95003 - 06 Test Type: CHRONIC Route: SKIN APPLICATION Species/Strain: MICE/B6C3F1	P18: INCIDENCE RA	Date Report Requested: 10/09/200 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI			
B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Subcutaneous Tissue, Hemorrhage				1 [2.0]	
MUSCULOSKELETAL SYSTEM					
Bone Osteopetrosis Cranium, Osteopetrosis Skeletal Muscle	(50) 2 [2.0] (1)	(49) 1 [2.0] (4)	(50) 1 [3.0] 2 [2.0] (1)	(50) (1)	
NERVOUS SYSTEM					
Brain Compression Congestion Hemorrhage Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte, Focal	(50) 1 [2.0] 2 [1.0]	(50) 5 [1.0] 2 [1.0]	(50) 4 [1.3]	(50) 1 [2.0] 1 [2.0] 5 [1.4] 1 [1.0] 1 [2.0]	
RESPIRATORY SYSTEM					
Lung Congestion Hemorrhage Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte Inflammation, Suppurative Inflammation, Chronic Metaplasia, Osseous Necrosis	(50) 2 [3.0] 2 [1.5] 1 [2.0] 8 [2.5] 1 [4.0] 1 [1.0] 1 [4.0]	(50) 3 [2.0] 6 [1.8] 3 [2.3]	(50) 1 [1.0] 2 [1.0] 8 [1.9] 1 [2.0] 1 [1.0]	(50) 2 [2.0] 12 [2.1]	
Thrombosis Alveolar Epithelium, Hyperplasia Nose Foreign Body Inflammation, Suppurative Inflammation, Chronic	5 [1.0] (50) 1 1 [2.0] 6 [1.3]	1 [1.0] 6 [1.8] (50) 6 [1.7]	5 [2.6] (50) 5 [2.0]	8 [2.8] (50) 3 2 [1.5] 3 [1.7]	
Inflammation, Chronic Active Respiratory Epithelium, Hyperplasia Respiratory Epithelium, Metaplasia,			2 [2.5] 1 [2.0]	2 [2.5] 1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

vietriyi trans-styryi

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Squamous Trachea Inflammation, Chronic	(50)	(50)	(50) 1 [2.0]	(50)	
SPECIAL SENSES SYSTEM					
Eye Atrophy Fibrosis	(49) 1 [4.0]	(48)	(48)	(45) 1 [4.0] 1 [3.0]	
Inflammation, Chronic Inflammation, Chronic Active Cornea, Hyperplasia Cornea, Necrosis	1 [2.0]	1 [2.0] 1 [2.0]	1 [2.0] 1 [2.0]	1 [4.0] 4 [2.8] 4 [3.0] 1 [3.0]	
Retina, Vacuolization Cytoplasmic Harderian Gland Fibrosis Hyperplasia	(48) 1 [2.0]	(50)	1 [2.0] (50)	(50)	
Hyperplasia Hyperplasia, Focal Inflammation, Chronic Metaplasia, Osseous	2 [2.0] 3 [2.0]	1 [4.0] 2 [2.0] 3 [2.0]	1 [1.0]	3 [2.0] 2 [2.0] 1 [2.0]	
URINARY SYSTEM					
Kidney Casts Granular Casts Protein	(48)	(49) 2 [2.0] 1 [1.0]	(49)	(47)	
Cyst Hyperplasia, Lymphoid Hyperplasia, Oncocytic	15 [2.0] 10 [2.0] 1 [2.0]	13 [2.0] 18 [2.0]	7 [2.0] 10 [2.0]	9 [2.0] 18 [2.0]	
Infarct Inflammation, Suppurative Inflammation, Chronic	2 [2.5] 1 [1.0]	4 [2.0] 1 [2.0]		2 [2.0]	
Metaplasia, Osseous Nephropathy Capsule, Fibrosis Capsule, Pigmentation	6 [1.8] 41 [2.0]	8 [1.8] 43 [2.0]	4 [1.8] 45 [1.8]	3 [2.0] 45 [1.6] 1 [2.0] 1 [2.0]	
Papilla, Necrosis Pelvis, Dilatation Renal Tubule, Accumulation, Hyaline	1 [3.0] 1 [2.0]	3 [2.0] 1 [2.0]		1 [2.0] 1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

TDMS No. 95003 - 06

Test Type: CHRONIC **Route: SKIN APPLICATION**

Species/Strain: MICE/B6C3F1

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Droplet					
Renal Tubule, Dilatation, Focal		1 [1.0]		1 [2.0]	
Renal Tubule, Hyperplasia	2 [1.0]	2 [2.5]	2 [1.0]	L - J	
Renal Tubule, Necrosis			1 [4.0]	1 [1.0]	
Renal Tubule, Pigmentation		1 [3.0]		1 [1.0]	
Urethra	(1)	(0)	(0)	(0)	
Bulbourethral Gland, Necrosis	1 [4.0]				
Urinary Bladder	(49)	(48)	(49)	(48)	
Edema		3 [2.7]	. ,		
Hemorrhage	1 [2.0]				
Hyperplasia, Lymphoid	1 [2.0]	2 [2.5]	1 [2.0]	1 [2.0]	
Necrosis	1 [2.0]	1 [2.0]			

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

neuryi irans-siyiyi i

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
isposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths					
Moribund Sacrifice	6	6	10	7	
Natural Death Survivors	7	5	9	6	
Terminal Sacrifice	37	39	31	37	
Animals Examined Microscopically	50	50	50	50	
LIMENTARY SYSTEM					
Gallbladder	(44)	(47)	(40)	(43)	
Intestine Large, Cecum	(47)	(49)	(45)	(46)	
Edema			1 [2.0]		
Intestine Large, Colon	(44)	(47)	(42)	(44)	
Edema		1 [2.0]	2 [1.5]		
Inflammation, Acute Intestine Large, Rectum	(45)	1 [1.0] (48)	(43)	(44)	
Intestine Small, Duodenum	(43)	(47)	(43)	(44)	
Hyperplasia	(40)	1 [2.0]	(+0)	(++)	
Ulcer		1 [4.0]			
Intestine Small, Ileum	(43)	(45)	(42)	(45)	
Dilatation	. ,		1 [4.0]	. ,	
Inflammation, Acute		2 [2.0]	1 [2.0]		
Epithelium, Hyperplasia	(10)	(10)	1 [3.0]		
Intestine Small, Jejunum Necrosis	(43)	(46)	(42)	(44)	
Necrosis Liver	(50)	(50)	1 [1.0] (50)	(49)	
Angiectasis	(50) 3 [2.7]	3 [2.0]	(00)	(49)	
Basophilic Focus	3 [2.7] 4	2	3	2	
Bile Stasis		1 [2.0]	1 [3.0]	-	
Clear Cell Focus	6	3	5	4	
Congestion		1 [2.0]			
Eosinophilic Focus	16	13	14	15	
Fatty Change	1 [3.0]		0.11.53	0.14.53	
Hematopoietic Cell Proliferation	13 [1.2]	15 [1.1]	6 [1.0]	8 [1.0]	
Hemorrhage	2 [3.0]	1 [1.0]	1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

TDMS No. 95003 - 06

Test Type: CHRONIC **Route: SKIN APPLICATION**

Species/Strain: MICE/B6C3F1

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Hyperplasia, Lymphoid Infarct	2 [2.0]	5 [2.0] 1 [4.0]	1 [2.0] 1 [3.0]	6 [2.0]	
Inflammation, Chronic Karyomegaly	1 [3.0]		1 [2.0]		
Mixed Cell Focus	1	2	2		
Necrosis, Focal	6 [2.0]	10 [2.2]	10 [1.9]	5 [1.6]	
Vacuolization Cytoplasmic	([0, 0]	2 [2.0]			
Centrilobular, Necrosis Hepatocyte, Hypertrophy	1 [2.0]	1 [4.0]	5 [1.6]		
Hepatocyte, Vacuolization Cytoplasmic	1 [2.0]	2 [2.5]	5[1.0]	1 [3.0]	
Kupffer Cell, Pigmentation	2 [2.0]	2 [2.0]	2 [1.5]	1 [0:0]	
Mesentery	(16)	(22)	(17)	(13)	
Congestion	1 [2.0]				
Fibrosis	1 [2.0]	4 [0, 0]		4 [0 0]	
Hemorrhage Fat, Necrosis	15 [0 1]	1 [2.0] 21 [2.0]	17 [1.8]	1 [2.0]	
Parcreas	15 [2.1] (50)	(50)	(49)	11 [1.9] (47)	
Atrophy	2 [2.5]	4 [2.8]	1 [1.0]	3 [4.0]	
Cyst	-[]	2 [2.0]	2 [2.0]	3 [2.0]	
Fibrosis			1 [1.0]		
Hyperplasia, Lymphoid	1 [2.0]		2 [2.0]	1 [2.0]	
Inflammation, Granulomatous, Chronic Active			1 [4.0]		
Inflammation, Focal, Chronic		1 [3.0]			
Metaplasia, Hepatocyte			1 [1.0]		
Mineralization Necrosis		1 [2 0]	1 [2.0]		
Acinus, Hyperplasia, Focal	1 [2.0]	1 [2.0]		1 [2.0]	
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy	1 [1.0]	()	1 [3.0]		
Hyperplasia, Lymphoid	20 [2.0]	14 [2.0]	12 [2.1]	23 [2.0]	
Mineralization	3 [1.0]	1 [1.0]	()	()	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Edema Erosion	2 [1.0]	1 [1.0] 1 [1.0]	1 [4.0]		
Inflammation, Chronic	2 [1.0] 1 [2.0]	1 [2.0]	2 [1.5]		
Ulcer	2 [1.5]	2 [2.5]	4 [2.3]	5 [1.8]	
Epithelium, Hyperplasia	6 [2.0]	7 [2.0]	10 [2.4]	4 [2.3]	
Stomach, Glandular	(48)	(48)	(48)	(46)	
Cyst	5 [2.0]	3 [2.0]	8 [2.0]	4 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Edema Erosion		3 [1.3]	1 [3.0] 1 [1.0]	1 [2.0]
Foreign Body		5 [1.5]	1[1.0]	1 [1.0]
Inflammation, Acute				1 [1.0]
Mineralization	1 [1.0]	1 [1.0]	1 [1.0]	2 [1.5]
	1 [2.0]		1 [3.0]	
Epithelium, Hyperplasia	1 [2.0]		1 [2.0]	
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	8 [1.0]	12 [1.2]	10 [1.1]	9 [1.3]
Mineralization	1 [1.0]	1 [1.0]	3 [1.3]	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	6 [1.3]	2 [2.0]	4 [1.3]	1 [1.0]
Degeneration, Fatty	3 [3.3]	2 [2.5]	1 [2.0]	1 [1.0]
Hematopoietic Cell Proliferation	2 [1.5]		2 [2.5]	2 [1.5]
Hyperplasia, Focal	1 [2.0]	2 [1.0]	1 [1.0]	
Hypertrophy, Focal		2 [2.5]	1 [1.0]	4 [2.0]
Capsule, Hyperplasia	48 [2.3]	47 [2.2]	49 [2.2]	50 [2.1]
Adrenal Medulla	(50)	(49)	(50)	(50)
Hyperplasia	2 [1.5]	4 [2.3]	2 [2.0]	3 [1.7]
Islets, Pancreatic Angiectasis	(50)	(50)	(49)	(47) 1 [3.0]
Hyperplasia	4 [1.0]	2 [1.5]	4 [1.3]	5 [1.2]
Parathyroid Gland	(46)	(48)	(46)	(46)
Inflammation, Chronic			(10)	1 [2.0]
Pituitary Gland	(47)	(49)	(50)	(46)
Pars Distalis, Angiectasis	\ /	2 [2.0]	2 [3.0]	1 [3.0]
Pars Distalis, Cyst	1 [2.0]		3 [2.0]	1 [2.0]
Pars Distalis, Hyperplasia	3 [4.0]	1 [4.0]		
Pars Distalis, Hyperplasia, Focal	6 [2.7]	6 [2.3]	12 [2.1]	5 [1.6]
Pars Intermedia, Cyst	1 [2.0]			
Pars Intermedia, Hyperplasia, Focal	1 [2.0]		1 [1.0]	
Pars Intermedia, Hypertrophy	(40)	(50)	(40)	1 [2.0]
Thyroid Gland	(49)	(50)	(49)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Infiltration Cellular, Lymphocyte	1 [2.0]				
Inflammation, Acute Inflammation, Chronic		1 [1.0]	1 [2.0]	1 [2.0]	
Ultimobranchial Cyst		1[1.0]	1 [2:0]	1 [2.0]	
Bilateral, Follicular Cell, Hyperplasia, Diffuse		1 [3.0]			
Follicle, Degeneration, Focal	30 [1.7]	31 [2.2]	35 [1.9]	31 [1.9]	
Follicular Cell, Hyperplasia		1 [1.0]	1 [3.0]	2 [1.5]	
Follicular Cell, Hyperplasia, Focal	2 [2.0]	2 [2.5]	2 [1.5]		
GENERAL BODY SYSTEM					
Tissue NOS	(3)	(2)	(4)	(0)	
Fibrosis Abdominal, Fat, Inflammation, Chronic	1 [3.0]		4 [0 0]		
Active			1 [2.0]		
GENITAL SYSTEM					
Clitoral Gland	(48)	(49)	(50)	(46)	
Inflammation, Chronic	2 [3.0]	1 [3.0]	(()	1 [3.0]	
Ovary	(49)	(50)	(48)	(50)	
Angiectasis Cyst	1 [2.0] 9 [2.0]	1 [3.0] 17 [2.0]	6 [2.0]	1 [3.0] 10 [2.0]	
Hemorrhage	9 [2.0] 9 [2.7]	15 [2.1]	0 [2.0] 17 [2.1]	18 [2.0]	
Inflammation, Chronic	9 [2.7]	15 [2.1]	1 [4.0]	16 [2.0]	
Mineralization			1 [2.0]		
Thrombosis	1 [3.0]	2 [4.0]	5 [3.2]	3 [3.3]	
Interstitial Cell, Hyperplasia	3 [2.3]	=[]	1 [3.0]	0 [0:0]	
Uterus	(50)	(50)	(49)	(50)	
Angiectasis	1 [2.0]	1 [2.0]			
Hemorrhage	1 [4.0]		1 [3.0]	1 [4.0]	
Hyperplasia, Cystic	49 [3.4]	46 [3.2]	43 [3.2]	47 [3.1]	
Hyperplasia, Histiocytic				1 [4.0]	
Metaplasia, Osseous				1 [1.0]	
Pigmentation		1 [3.0]	([0, 0]		
Myometrium, Hypertrophy			1 [3.0]		
Vagina	(1)	(2)	(1)	(0)	
Hyperplasia, Squamous		1 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

MS No. 95003 - 06 st Type: CHRONIC ute: SKIN APPLICATION ecies/Strain: MICE/B6C3F1	P18: INCIDENCE RA	Date Report Requested: 10/09/200 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI			
B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Inflammation, Chronic Necrosis		1 [4.0] 1 [4.0]			
HEMATOPOIETIC SYSTEM					
Bone Marrow Angiectasis Hyperplasia, Megakaryocyte Infiltration Cellular, Histiocyte	(50)	(50)	(50) 1 [3.0] 1 [2.0]	(50) 1 [2.0] 1 [3.0]	
Myelofibrosis Myeloid Cell, Hyperplasia Lymph Node	1 [2.0] (13)	(11)	1 [3.0] (15)	1 [2.0] 1 [2.0] (14)	
Ectasia Fibrosis Hematopoietic Cell Proliferation	2 [2.5]	3 [3.7] 1 [4.0]	6 [3.8]	3 [3.7] 1 [2.0]	
Hemorrhage Hyperplasia, Lymphoid Bronchial, Hyperplasia, Lymphoid	1 [3.0]	3 [3.7] 1 [2.0]	4 [2.8]	2 [3.5] 1 [4.0]	
Iliac, Ectasia Iliac, Hemorrhage Iliac, Hyperplasia, Lymphoid Iliac, Infiltration Cellular, Histiocyte Renal, Ectasia	2 [2.5] 1 [2.0]		2 [2.0] 1 [3.0] 1 [2.0] 1 [4.0] 1 [2.0]	1 [4.0] 1 [4.0] 1 [2.0]	
Renal, Hyperplasia, Lymphoid Renal, Infiltration Cellular, Histiocyte Lymph Node, Mandibular	1 [2.0] (50)	(48)	1 [2.0] 1 [4.0] (46)	(50)	
Atrophy Ectasia Hemorrhage	2 [2.5]	1 [2.0] 2 [1.0]		4 [2.5] 1 [2.0]	
Hyperplasia, Histiocytic Hyperplasia, Lymphoid Lymph Node, Mesenteric Atrophy Ectasia	11 [1.9] (47) 5 [2.2]	7 [1.9] (49) 3 [1.7]	1 [3.0] 4 [2.5] (45) 2 [2.0] 1 [3.0]	2 [2.0] (48) 6 [2.2]	
Hematopoietic Cell Proliferation Hemorrhage Hyperplasia, Lymphoid	1 [4.0]	2 [2.0] 1 [3.0]	1 [2.0]	1 [2.0]	
Hyperplasia, Plasma Cell Infiltration Cellular, Neutrophil	1 [2.0] 1 [1.0]	1 [3.0] 1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

TDMS No. 95003 - 06	P18: INCIDEN

Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Spleen	(49)	(50)	(48)	(48)	
Angiectasis	1 [4.0]	00 [0 0]	04 [0 0]	00 10 01	
Hematopoietic Cell Proliferation	27 [2.9]	28 [2.9]	31 [3.2]	26 [2.8]	
Hyperplasia, Lymphoid Pigmentation	8 [1.4]	5 [2.2]	1 [3.0] 9 [1.6]	1 [1.0] 3 [2.3]	
Lymphoid Follicle, Atrophy	0 [1.4] 1 [4.0]	5 [2.2]	9 [1.0] 1 [1.0]	2 [3.0]	
Lymphoid Follicle, Hyperplasia	26 [1.5]	20 [1.9]	19 [1.8]	2 [5.0] 23 [1.6]	
Thymus	(50)	(46)	(46)	(48)	
Cyst	2 [2.0]	1 [2.0]	4 [2.0]	4 [2.0]	
Hemorrhage	6 [2.3]	7 [2.0]	10 [1.6]	9 [1.4]	
Hyperplasia, Lymphoid	1 [3.0]	r [2.0]	10 [1.0]	1 [3.0]	
INTEGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Hyperplasia	4 [1.5]	3 [2.0]	4 [1.3]	4 [2.5]	
Infiltration Cellular, Lymphocyte		1 [2.0]			
Inflammation, Chronic		1 [2.0]			
Pigmentation				1 [2.0]	
Skin	(50)	(50)	(50)	(50)	
Edema	1 [2.0]	3 [2.7]	2 [4.0]	1 [2.0]	
Hemorrhage	1 [3.0]	1 [4.0]			
Hyperkeratosis	3 [2.7]	4 [1.3]	3 [1.0]	12 [1.4]	
Hyperplasia, Melanocyte	1 [3.0]		2 [1.5]	3 [1.3]	
Inflammation, Acute	4 [4 0]	2 [2.5]	7 [4 0]	40.54.01	
Inflammation, Chronic	1 [1.0]	4 [1.3]	7 [1.0]	18 [1.2]	
Inflammation, Chronic Active	1 [3.0]				
	1 [3.0]	2 [4 0]		0 [4 0]	
Epidermis, Hyperplasia	2 [3.0]	2 [1.0]	2 [1.5]	9 [1.2]	
Epidermis, Site Of Application,	7 [1.3]	11 [1.0]	31 [1.5]	33 [1.7]	
Hyperplasia	4 [0 0]		1 [2 0]	4 [2 0]	
Site Of Application, Erosion	1 [2.0]	1 [2 0]	1 [2.0]	1 [3.0]	
Site Of Application, Hemorrhage Site Of Application, Hyperkeratosis	0 [1 4]	1 [2.0] 16 [1.4]	27 [1 6]	26 [1 7]	
	9 [1.4]	10[1.4]	37 [1.6]	36 [1.7]	
Site Of Application, Hyperplasia	2 [4 0]	2 [1 0]	10 11 22	1 [3.0]	
Site Of Application, Hyperplasia, Melanocyte	3 [1.0]	3 [1.0]	33 [1.2]	36 [2.1]	
Site Of Application, Inflammation, Acute		1 [2.0]			
Site Of Application, Inflammation, Acute	7 [1.3]	11 [1.3]	33 [1.5]	38 [1.6]	
	7 [1.0]	11[1.0]	55[1.5]	56 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

MS No. 95003 - 06 st Type: CHRONIC ute: SKIN APPLICATION ecies/Strain: MICE/B6C3F1	P18: INCIDENCE RA	Date Report Requested: 10/09/200 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI			
B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Chronic Site Of Application, Ulcer Site Of Application, Subcutaneous Tissue, Metaplasia, Osseous			2 [2.5]	4 [3.3] 1 [2.0]	
Subcutaneous Tissue, Hemorrhage Subcutaneous Tissue, Necrosis			1 [2.0] 1 [2.0]		
MUSCULOSKELETAL SYSTEM					
Bone Cranium, Fibrosis Cranium, Osteopetrosis Femur, Fibro-Osseous Lesion Femur, Hyperostosis	(49) 2 [1.5] 12 [1.9]	(50) 1 [3.0] 1 [1.0] 7 [1.3] 5 [1.8]	(50) 1 [2.0] 12 [1.9] 1 [2.0]	(50) 1 [3.0] 2 [1.0] 10 [1.2] 6 [1.7]	
Vertebra, Arthrosis Skeletal Muscle Degeneration Inflammation, Chronic	(3) 1 [1.0]	(2) 1 [1.0]	(2)	1 [3.0] (3)	
NERVOUS SYSTEM					
Brain Compression Gliosis	(50)	(50) 3 [3.3]	(50) 2 [3.5]	(50) 3 [2.7] 1 [1.0]	
Hemorrhage Hyperplasia, Lymphoid Infiltration Cellular, Lipocyte Inflammation, Acute	4 [1.3] 3 [1.7]	2 [1.5] 2 [1.0]	2 [1.0] 2 [1.0] 1 [2.0] 1 [1.0]	2 [1.0] 3 [1.3]	
Inflammation, Chronic Metaplasia, Osseous Necrosis, Focal	4 [0 0]		1 [2.0]	1 [2.0] 1 [2.0] 2 [2.0]	
Meninges, Inflammation, Chronic Peripheral Nerve Degeneration Inflammation, Chronic	1 [2.0] (1) 1 [2.0] 1 [2.0]	(1)	(0)	(0)	

RESPIRATORY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Lung	(50)	(50)	(49)	(50)	
Congestion	1 [2.0]	1 [2.0]	1 [2.0]	2 [2.0]	
Fibrosis				1 [1.0]	
Hemorrhage	2 [2.0]	6 [1.5]	3 [1.0]	1 [1.0]	
Hyperplasia, Lymphoid				2 [2.0]	
Infiltration Cellular, Histiocyte	5 [2.0]	3 [2.3]	3 [2.0]	4 [2.0]	
Metaplasia, Osseous		1 [2.0]			
Mineralization	1 [1.0]				
Thrombosis	1 [2.0]		0.10.01		
Alveolar Epithelium, Hyperplasia	5 [1.6]	8 [1.8]	3 [2.3]	6 [1.8]	
Nose	(50)	(50)	(50)	(50)	
Foreign Body		4 [0 0]	1 [1.0]		
Hemorrhage	4 [0, 0]	1 [2.0]	0 [0 0]		
Inflammation, Chronic	1 [3.0]	2 [1.5]	2 [2.0]		
Glands, Cyst	(1)	1 [2.0]	(0)	(1)	
Pleura	(1)	(0)	(0)	(1)	
SPECIAL SENSES SYSTEM					
Eye	(47)	(50)	(48)	(47)	
Developmental Malformation				1 [2.0]	
Inflammation, Chronic		2 [1.0]	1 [2.0]	1 [2.0]	
Bilateral, Hemorrhage		1 [4.0]			
Bilateral, Retinal Detachment		1 [4.0]			
Bilateral, Optic Nerve, Necrosis		1 [4.0]			
Cornea, Hyperplasia		2 [1.0]	3 [1.3]	1 [2.0]	
Cornea, Inflammation, Chronic			1 [2.0]		
Retina, Degeneration		2 [1.5]			
Harderian Gland	(50)	(50)	(49)	(49)	
Cyst				1 [2.0]	
Fibrosis			1 [3.0]		
Hyperplasia	1 [3.0]				
Hyperplasia, Focal	2 [2.0]	5 [2.4]	5 [2.8]		
Inflammation, Chronic	8 [2.0]	1 [2.0]	3 [2.0]	3 [2.0]	
Bilateral, Hemorrhage		1 [4.0]			
URINARY SYSTEM					
Kidney	(49)	(50)	(48)	(47)	
	× /	· · /		· · ·	

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Nephropathy Papilla, Necrosis

Droplet

Urinary Bladder

Pelvis, Dilatation

Renal Tubule, Accumulation, Hyaline

Transitional Epithelium, Hyperplasia

Renal Tubule, Dilatation, Focal

Renal Tubule, Necrosis

Hyperplasia, Lymphoid

Inflammation, Chronic

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Requested: 10/09/2009

AVERAGE SEVERITY GRADES[b] Methyl trans-styryl ketone

CAS Number: 1896-62-4

1 [1.0]

2 [2.0]

1 [1.0]

(48)

10 [2.0]

1 [2.0]

1 [1.0]

(48)

8 [2.3]

Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 I ab. SRI

eies/Strain: MICE/B6C3F1					Lab: SRI	
B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG		
Casts Protein			1 [1.0]			
Cyst	2 [2.0]	1 [2.0]		3 [2.0]		
Hemorrhage				1 [2.0]		
Hyperplasia, Lymphoid	15 [2.1]	14 [2.0]	16 [2.1]	11 [2.1]		
Infarct	1 [1.0]	7 [1.7]	6 [2.2]	3 [2.0]		
Infiltration Cellular, Lipocyte	1 [2.0]					
Metaplasia, Osseous	2 [2.0]	3 [1.3]	3 [1.7]	2 [3.0]		
Mineralization	8 [1.1]	1 [1.0]	2 [1.0]	2 [1.0]		
Nephropathy	31 [1.4]	37 [1.2]	36 [1.5]	30 [1.2]		

3 [3.3]

1 [1.0]

(50)

6 [2.0]

1 [3.0]

1 [3.0]

(49)

11 [2.1]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion